The U.S. FDA granted Orphan Drug Designation for OBI Pharma Inc.’s first-in-class antibody drug conjugate (ADC) OBI-999 for the treatment of pancreatic cancer.
Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.
